Last reviewed · How we verify
Extension Period(JW0201)
Extension Period (JW0201) is a drug that extends the duration of action of a biologic.
Extension Period (JW0201) is a drug that extends the duration of action of a biologic. Used for Treatment of dry eye disease.
At a glance
| Generic name | Extension Period(JW0201) |
|---|---|
| Also known as | JW0201+C2022+C2203 |
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Extension Period (JW0201) is a drug that extends the duration of action of a biologic by binding to and stabilizing the biologic, thereby preventing its degradation. This allows the biologic to remain active in the body for a longer period, which can improve its efficacy and reduce the frequency of administration.
Approved indications
- Treatment of dry eye disease
Common side effects
- Eye irritation
Key clinical trials
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extension Period(JW0201) CI brief — competitive landscape report
- Extension Period(JW0201) updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI